BELITE BIO, INC
BLTENasdaq
$150.08
↓ -0.4%Jul 17 close · end-of-day
Price
1Y↑ +141.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.0B
Enterprise Value
$4.7B
P/E
—
P/S
—
P/B
6.5
EV/EBITDA
—
PEG
—
FCF Yield
-0.7%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$77.6M
Free Cash Flow (TTM)
-$37.1M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-10.1%
ROIC
-15.9%
Debt / Equity
—
Net Cash
$352.9M
Return 1Y
+146.1%
Company profile
Belite Bio, Inc engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue.
- CEO
- Yue H. Lin
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- California
- Website
- belitebio.com
Management & directors
- Scholl Hendrik PeterChief Medical Officer
- Mata Nathan L.Chief Scientific Officer
- Chuang Hao-YuanChief Financial Officer
- Lin Yu-HsinChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$5.7M | -$9.8M | -$12.8M | -$31.7M | -$40.0M | -$84.2M |
| Net income | -$5.8M | -$9.7M | -$12.6M | -$31.6M | -$36.1M | -$77.6M |
| Diluted EPS | -$0.65 | -$1.01 | -$0.63 | -$1.19 | -$1.18 | -$2.31 |
| Operating cash flow | -$4.4M | -$7.5M | -$11.5M | -$29.8M | -$29.2M | -$37.0M |
| Free cash flow | — | -$7.5M | -$11.9M | -$29.9M | -$29.4M | -$37.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
No quarterly data.
Company news
Jul 10, 2026
Jul 6, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-18 | Scholl Hendrik Peter· Chief Medical Officer | Sale | 4,861 | $145.43 | $706,958.56 | filing |
| 2026-06-18 | Scholl Hendrik Peter· Chief Medical Officer | Sale | 3,748 | $144.66 | $542,192.05 | filing |
| 2026-06-18 | Scholl Hendrik Peter· Chief Medical Officer | Sale | 1,199 | $146.24 | $175,347.64 | filing |
| 2026-06-18 | Scholl Hendrik Peter· Chief Medical Officer | Sale | 96 | $147.11 | $14,122.56 | filing |
| 2026-06-18 | Scholl Hendrik Peter· Chief Medical Officer | Sale | 96 | $143.90 | $13,814.40 | filing |
| 2026-06-16 | Scholl Hendrik Peter· Chief Medical Officer | Sale | 3,140 | $139.57 | $438,260.48 | filing |
| 2026-06-16 | Scholl Hendrik Peter· Chief Medical Officer | Sale | 2,054 | $137.61 | $282,641.29 | filing |
| 2026-06-16 | Scholl Hendrik Peter· Chief Medical Officer | Sale | 1,897 | $143.55 | $272,314.35 | filing |
| 2026-06-16 | Scholl Hendrik Peter· Chief Medical Officer | Sale | 1,035 | $145.02 | $150,096.94 | filing |
| 2026-06-16 | Scholl Hendrik Peter· Chief Medical Officer | Sale | 784 | $138.18 | $108,330.53 | filing |
| 2026-06-16 | Scholl Hendrik Peter· Chief Medical Officer | Sale | 540 | $140.58 | $75,914.71 | filing |
| 2026-06-16 | Scholl Hendrik Peter· Chief Medical Officer | Sale | 450 | $142.20 | $63,988.11 | filing |
| 2026-06-16 | Scholl Hendrik Peter· Chief Medical Officer | Sale | 100 | $141.83 | $14,183.00 | filing |
| 2026-05-07 | MATA NATHAN L.· Chief Scientific Officer | Sale | 428 | $153.56 | $65,725.18 | filing |
| 2026-05-07 | MATA NATHAN L.· Chief Scientific Officer | Sale | 226 | $152.45 | $34,453.09 | filing |
| 2026-05-07 | MATA NATHAN L.· Chief Scientific Officer | Sale | 9 | $155.25 | $1,397.28 | filing |
| 2026-05-07 | MATA NATHAN L.· Chief Scientific Officer | Sale | 3 | $154.61 | $463.83 | filing |
| 2026-05-06 | MATA NATHAN L.· Chief Scientific Officer | Sale | 424 | $152.67 | $64,732.80 | filing |
| 2026-05-06 | MATA NATHAN L.· Chief Scientific Officer | Sale | 240 | $154.41 | $37,058.81 | filing |
| 2026-05-06 | MATA NATHAN L.· Chief Scientific Officer | Sale | 128 | $153.42 | $19,637.54 | filing |
| 2026-05-06 | MATA NATHAN L.· Chief Scientific Officer | Sale | 100 | $156.00 | $15,600.00 | filing |
| 2026-05-06 | MATA NATHAN L.· Chief Scientific Officer | Sale | 100 | $155.97 | $15,597.00 | filing |
| 2026-05-06 | MATA NATHAN L.· Chief Scientific Officer | Sale | 8 | $151.57 | $1,212.56 | filing |
| 2026-05-05 | MATA NATHAN L.· Chief Scientific Officer | Sale | 363 | $154.44 | $56,062.92 | filing |
| 2026-05-05 | MATA NATHAN L.· Chief Scientific Officer | Sale | 173 | $155.48 | $26,897.54 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.